Remove IPO Remove Public Trading Remove S&P
article thumbnail

Will There Be an IPO for a Specialty Consulting Company in 2024?

Focus Investment Banking

The S&P 500 has recently traded near 4800, close to its record at the end of 2021. In that environment, very few firms sought IPOs, and there was a major slowdown in overall exits, whether private or public. There are only a few publicly traded companies in specialty consulting. As 2024 starts, the U.S.

IPO 52
article thumbnail

Why Take-Private Dealmaking Remains Attractive for PE Investors

OfficeHours

First, private equity identifies the publicly traded company they believe is undervalued or could perform better as a private entity without the pressures of being a public entity (e.g. More specifically, private equity investors in 2023 have noticed the decline in the value of public market companies.

Investors 100
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

10-23-2023 Newsletter: Why Take-Private Dealmaking Remains Attractive for PE Investors

OfficeHours

First, private equity identifies the publicly traded company they believe is undervalued or could perform better as a private entity without the pressures of being a public entity (e.g. More specifically, private equity investors in 2023 have noticed the decline in the value of public market companies.

Investors 130
article thumbnail

Sports Investment Banking: How to Win the Super Bowl and the World Cup in the Same Year

Mergers and Inquisitions

However, one common point across all the verticals is that IPOs are not common because there aren’t that many publicly traded sports teams, stadiums, or arenas. SPAC IPOs for esports companies were “hot” for a short period in 2021, but they seem to have died off by now.

article thumbnail

Cooley’s 2021 Life Sciences M&A Year in Review

Cooley M&A

While 2020’s M&A landscape was characterized by whiplash volatility from choppy deal activity in the first half of the year to a surge in volume in the second half, that momentum accelerated in 2021, with no signs of slowing down heading into 2022. on transactions over 2019’s mega?mergers. General trends in life sciences M&A.

M&A 40